Search

everythinglearnresearchcommunity

for

Search:↓

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.

Hair regrowth improved, but quality of life did not.

Baricitinib was effective in treating both early and late onset alopecia areata.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.

Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.

Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.

The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

The drug combination was safe and showed promise in treating advanced tumors.

The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.

GT20029 showed some hair growth improvement, but longer studies are needed for better results.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

MK-0773 safely increased muscle mass but did not improve muscle strength or function in elderly women with sarcopenia.

New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

Weekly bicalutamide is safe and effective, with 50 mg/week recommended.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

Clinical trials should use innovative designs and biomarkers to improve precision therapy and patient outcomes.

The document's conclusion cannot be provided because the content is not available.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.